These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31316516)

  • 1. Peripheral PD-1
    Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
    Front Immunol; 2019; 10():1470. PubMed ID: 31316516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
    Kohli A; Kattakuzhy S; Sidharthan S; Nelson A; McLaughlin M; Seamon C; Wilson E; Meissner EG; Sims Z; Silk R; Gross C; Akoth E; Tang L; Price A; Jolley TA; Emmanuel B; Proschan M; Teferi G; Chavez J; Abbott S; Osinusi A; Mo H; Polis MA; Masur H; Kottilil S
    Ann Intern Med; 2015 Dec; 163(12):899-907. PubMed ID: 26595450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection.
    Han JW; Sung PS; Kim KH; Hong SH; Shin EC; Jun Song M; Park SH
    J Infect Dis; 2019 Sep; 220(8):1290-1301. PubMed ID: 31152667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
    Nguyen THT; Guedj J; Uprichard SL; Kohli A; Kottilil S; Perelson AS
    Sci Rep; 2017 Aug; 7(1):10233. PubMed ID: 28860456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
    Missale G; Pilli M; Zerbini A; Penna A; Ravanetti L; Barili V; Orlandini A; Molinari A; Fasano M; Santantonio T; Ferrari C
    Gut; 2012 Jul; 61(7):1076-84. PubMed ID: 22337949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.
    Kroy DC; Ciuffreda D; Cooperrider JH; Tomlinson M; Hauck GD; Aneja J; Berger C; Wolski D; Carrington M; Wherry EJ; Chung RT; Tanabe KK; Elias N; Freeman GJ; de Kruyff RH; Misdraji J; Kim AY; Lauer GM
    Gastroenterology; 2014 Feb; 146(2):550-61. PubMed ID: 24148617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.
    Wu SF; Tseng CW; Ho YC; Chen YC; Ko PH; He YT; Tseng KC
    Dig Dis Sci; 2020 May; 65(5):1385-1395. PubMed ID: 31559553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
    Virlogeux V; Berthillon P; Bordes I; Larrat S; Crouy S; Scholtès C; Pradat P; Maynard M; Zoulim F; Leroy V; Chemin I; Trépo C; Petit MA
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):313-318. PubMed ID: 29551607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    Llorens-Revull M; Costafreda MI; Rico A; Guerrero-Murillo M; Soria ME; Píriz-Ruzo S; Vargas-Accarino E; Gabriel-Medina P; Rodríguez-Frías F; Riveiro-Barciela M; Perales C; Quer J; Sauleda S; Esteban JI; Bes M
    PLoS One; 2021; 16(7):e0254243. PubMed ID: 34242330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C.
    Welker MW; Hofmann WP; Lange CM; Herrmann E; Sarrazin C; Zeuzem S; Kronenberger B
    Scand J Gastroenterol; 2011 Jul; 46(7-8):973-80. PubMed ID: 21615225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.
    Szereday L; Meggyes M; Berki T; Miseta A; Farkas N; Gervain J; Par A; Par G
    Clin Exp Med; 2020 May; 20(2):219-230. PubMed ID: 32108916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
    Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
    J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.